 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: The occurrence of immune-related adverse events and decreased renal function in patients with genitourinary system cancer treated with ICI

Eur J Cancer: The occurrence of immune-related adverse events and decreased renal function in patients with genitourinary system cancer treated with ICI

 Last Update: 2021-09-18
 Source: Internet
 Author: User

Tags

1 3 dioxolane

immune system structure

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The effect of immune checkpoint inhibitors (ICIs) treatment on renal function in patients with cancer of the genitourinary system is unclear

immunity

This study is a retrospective cohort study that included patients with renal cell carcinoma (RCC) and urothelial carcinoma who received ICI treatment at two major cancer centers from 2012 to 2018

Cumulative incidence of reduced eGFR in patients with two cancers> 20%

A total of 637 patients were enrolled: 320 (50%) patients were RCC, and 317 (50%) were urothelial carcinoma

irAE, AKI, and persistent eGFR reduction are common, with incidences of 33%, 25%, and 16%, respectively

Cumulative incidence of persistent eGFR reduction in patients with irAE within 12 months

Among patients who survived for 1 year or more, the occurrence of non-renal irAEs was associated with a significantly higher risk of persistent eGFR reduction (aHR 1.

The occurrence of non-renal irAE is associated with a significantly higher risk of persistent eGFR reduction.

AKI and sustained eGFR reduction are common in patients with genitourinary cancer who are treated with ICI

Original source:

Seethapathy Harish,Street Sarah,Strohbehn Ian et al.

Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.